CovInnovations™ Submits Pre-IND, Engages BARDA
Key management personnel from CovInnovations™ attended the Institute for Biomedical Entrepreneurship (IBE) conference in Boston, meeting and making connections with leaders of multiple sectors of the bio tech industry. IBE brings specialized know-how and funding to biomedical researchers and innovators with educational programs and hands-on training that will help them become more aware of how to make their discoveries end up in the marketplace.
The company completed its submittal for Pre-IND authorization, which is a request from a clinical study sponsor to obtain FDA authorization to administer an investigational drug or biological product to humans.
CovInnovations™ encourages qualified investors to become a part of this groundbreaking journey. As the coronavirus pandemic infection rate continues to explode, investors will have the opportunity to participate in this innovative treatment program that has proven to reduce symptom severity and mortality for late-stage COVID-19 patients. CovInnovations™ currently has a pending application for FDA Investigative New Drug (IND) authorization and is engaged in productive communications with the Biological Advance Research Development Agency (BARDA)for funding for Phase 3 testing.
BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats through an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).
About CovArrest™
This new drug is composed of two current FDA-approved drugs that work synergistically to attack the same disease and are both metabolized by the same liver enzymes. One of the components of CovArrest™ showed significant success in a retrospective review completed in December 2020. This study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction in length of hospital stay (p<0.01). The treated group and the control group both received standard of care treatment as of 6/2020. Patients in the group provided the drug had a 93.6% survival rate as compared to the control group which had a survival rate of 78.5%. Those who did not survive appeared to experience a resurgence of viral replication or an insufficiently suppressed immune response, leading to the addition of the second component of CovArrest™. A subsequent cohort of 11 patients with the combined drug achieved 100% survival.
ABOUT CovInnovations™
CovInnovations™ creates technologies and solutions directly related to the COVID-19 pandemic. The company’s patent-pending treatments seek to create a new standard of care in the battle against this disease. CovInnovations™ products feature groundbreaking technologies that assess, diagnose and treat COVID-19 with the goal of integrating our world back to pre-pandemic times. The company was founded by Dr. Aury Nagy, M.D. FAANS, a neurosurgeon practicing in Las Vegas.
For further information, visit: www.covinnovations.com.
FORWARD LOOKING STATEMENT: Various statements contained in this presentation, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning the timing and success of strategies, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. These assumptions include, among others, our projections and expectations regarding: market trends litigation, our ability to create an opportunity with attractive current yields and upside. While we consider these expectations and assumptions to be somewhat reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Investors should not place undue reliance on these forward-looking statements. We undertake no obligation to update any forward-looking statements to conform to actual results or changes in our expectations, unless required by applicable law.